index - CRCL-Résistance hormonale, méthylation et cancer du sein

Armelle Dufresne, Valéry Attignon, Anthony Ferrari, Laurie Tonon, Sandrine Boyault, et al.. Added value of whole‐exome and RNA sequencing in advanced and refractory cancer patients with no molecular‐based treatment recommendation based on a 90‐gene panel. Cancer Medicine, 2024, 13 (7), pp.e7115. ⟨10.1002/cam4.7115⟩. ⟨hal-04646005⟩
Aina Bellver-Sanchis, Qizhi Geng, Gemma Navarro, Pedro A Ávila-López, Júlia Companys-Alemany, et al.. G9a Inhibition Promotes Neuroprotection through GMFB Regulation in Alzheimer’s Disease. Aging and disease, 2024, 15, pp.311-337. ⟨10.14336/ad.2023.0424-2⟩. ⟨hal-04481784⟩
Panagiotis Tsimpos, Simon Desiderio, Pauline Cabochette, Philippe Poelvoorde, Sadia Kricha, et al.. Loss of G9a does not phenocopy the requirement for Prdm12 in the development of the nociceptive neuron lineage. Neural Development, 2024, 19, pp.1. ⟨10.1186/s13064-023-00179-7⟩. ⟨hal-04481763⟩
Alexandre Casanova, Gael Roth, Simone Hausmann, Xiaoyin Lu, Ludivine Bischoff, et al.. Cytoskeleton remodeling induced by SMYD2 methyltransferase drives breast cancer metastasis. Cell Discovery, 2024, 10 (1), pp.12. ⟨10.1038/s41421-023-00644-x⟩. ⟨hal-04245506⟩
Jean-Marc Vanacker, Christelle Forcet. ERRα: unraveling its role as a key player in cell migration. Oncogene, 2024, 43 (6), pp.379 - 387. ⟨10.1038/s41388-023-02899-w⟩. ⟨hal-04727434⟩
Garazi Ruiz de Azua, Isabelle Kousignian, Ines Vaz-Luis, Antonio Di Meglio, Elsa Caumette, et al.. Sustainable return to work among breast cancer survivors. Cancer Medicine, 2023, ⟨10.1002/cam4.6467⟩. ⟨hal-04196116⟩

Derniers manuscrits de l'équipe

Chiffres clés